RARE Stock Balance Sheets

Ultragenyx Pharmaceutical Quarterly Balance Sheets Chart

Quarterly

Annual

Goodwill

Account Receivables

Cash and Cash Eq

Account Payables

Inventory

Ultragenyx Pharmaceutical Quarterly Balance Sheets Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31

assets
current assets:
cash and cash equivalents	176,306,000	127,055,000	173,729,000	150,619,000	480,693,000	112,250,000	213,584,000	72,575,000	102,059,000	85,768,000	132,944,000	391,651,000	159,868,000	153,988,000	307,584,000	197,538,000	290,875,000	383,794,000	713,526,000	197,486,000	335,639,000	298,190,000	433,584,000	122,577,000	131,337,000	269,712,000	113,432,000	82,956,000	110,854,000	226,730,000	100,488,000	60,407,000	90,751,000	159,501,000	161,120,000	142,280,000	55,069,000	70,763,000	93,569,000	166,686,000	52,351,000	178,040,000	24,324,000	53,387,000	17,452,000	55,447,000	7,427,000
marketable debt securities	311,279,000	367,385,000	436,296,000	470,989,000	283,128,000	299,830,000	363,625,000	369,519,000	449,922,000	543,586,000	614,818,000	497,024,000	382,927,000	444,333,000	432,612,000	539,579,000	554,881,000	581,614,000	488,007,000
accounts receivable	124,464,000	98,839,000	121,801,000	93,301,000	105,982,000	100,253,000	73,390,000	79,263,000	70,523,000	42,991,000	40,445,000	31,164,000	37,207,000	28,369,000	28,432,000	25,383,000	24,720,000	25,032,000	23,093,000	27,762,000	14,893,000	29,327,000	32,844,000	23,121,000	20,901,000	15,628,000	12,740,000	9,155,000	17,425,000	3,671,000	5,172,000
inventory	46,498,000	46,031,000	45,007,000	43,334,000	40,137,000	35,907,000	33,969,000	31,802,000	28,256,000	26,616,000	26,766,000	21,849,000	21,079,000	17,809,000	16,231,000	15,191,000	15,083,000	12,462,000	13,048,000	14,457,000	11,061,000	11,375,000	11,546,000	14,138,000	13,632,000	10,948,000	7,065,000	5,556,000	3,342,000	2,068,000	757,000
prepaid expenses and other assets	61,241,000	59,845,000	40,290,000
total current assets	719,788,000	699,155,000	817,123,000	799,608,000	964,640,000	595,967,000	732,184,000	599,188,000	702,137,000	766,336,000	883,899,000	1,012,668,000	678,542,000	707,519,000	856,604,000	846,884,000	949,492,000	1,070,936,000	1,295,304,000	872,003,000	906,039,000	894,318,000	851,017,000	613,486,000	699,431,000	786,887,000	522,369,000	567,480,000	604,743,000	581,580,000	269,583,000	390,903,000	419,794,000	444,685,000	401,695,000	416,785,000	411,084,000	430,234,000	450,207,000	460,707,000	336,530,000	350,514,000	193,416,000	206,741,000	158,216,000	169,636,000	55,225,000
property, plant, and equipment	255,763,000	260,906,000	265,929,000	272,448,000	278,707,000	285,111,000	290,566,000	296,811,000	288,990,000	277,873,000	259,726,000	234,614,000	207,381,000	177,073,000	141,247,000	119,069,000	104,568,000		73,515,000
intangible assets	174,733,000	176,524,000	178,314,000	164,942,000	166,243,000	165,045,000	166,271,000	157,302,000	158,237,000	159,171,000	160,105,000	158,401,000	159,196,000	159,992,000	130,788,000	130,869,000	130,950,000	131,031,000	131,113,000	131,194,000	131,275,000	129,000,000	129,000,000	129,020,000	129,069,000	129,086,000	129,223,000	130,232,000	132,776,000	137,122,000	141,545,000
goodwill	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000	44,406,000
other assets	60,121,000	62,373,000	62,680,000	41,365,000	54,700,000	47,727,000	47,616,000	27,896,000	26,489,000	22,259,000	16,846,000	18,285,000	21,144,000	21,218,000	20,558,000	16,419,000	12,668,000	8,929,000	8,812,000	5,092,000	2,627,000	4,862,000	3,471,000	3,111,000	3,181,000	2,660,000	3,514,000	3,199,000	3,239,000	1,574,000	1,315,000	1,345,000	1,736,000	1,762,000	1,837,000	1,868,000	1,446,000	2,063,000	595,000	734,000	790,000	781,000	774,000	825,000	1,129,000	550,000	2,648,000
total assets	1,306,265,000	1,311,927,000	1,503,456,000	1,538,363,000	1,618,437,000	1,307,080,000	1,491,013,000	1,238,140,000	1,311,310,000	1,383,404,000	1,545,444,000	1,618,474,000	1,320,627,000	1,384,029,000	1,522,397,000	1,484,801,000	1,512,444,000	1,597,763,000	1,759,555,000	1,268,385,000	1,314,041,000	1,233,140,000	1,135,496,000	879,944,000	958,927,000	1,007,759,000	719,558,000	765,145,000	806,022,000	817,350,000	490,753,000	435,047,000	497,542,000	545,822,000	540,626,000	515,166,000	481,951,000	524,184,000	559,569,000	602,130,000	343,004,000	355,840,000	197,967,000	210,931,000	162,586,000	172,707,000	59,649,000
liabilities, noncontrolling interest and stockholders' equity
current liabilities:
accounts payable	34,242,000	47,450,000	38,756,000	35,990,000	59,807,000	40,972,000	42,114,000	33,357,000	42,115,000	58,981,000	43,274,000	23,533,000	34,213,000	23,685,000	17,138,000	15,575,000	21,790,000	15,744,000	12,923,000	10,850,000	9,014,000	14,405,000	12,871,000	13,460,000	8,743,000	12,664,000	12,275,000	8,198,000	10,314,000	7,569,000	8,886,000	9,288,000	11,876,000	8,345,000	5,364,000	6,616,000	6,954,000	6,012,000	2,942,000	4,422,000	10,171,000	5,755,000	4,857,000	4,161,000	3,590,000	3,495,000	1,437,000
accrued liabilities	180,792,000	173,007,000	240,973,000	185,028,000	154,421,000	149,133,000	196,486,000	178,622,000	167,656,000	144,404,000	204,678,000	189,051,000	170,355,000	126,356,000	145,555,000	109,660,000	91,060,000	82,699,000	108,491,000	79,653,000	71,887,000	67,719,000	83,194,000	69,557,000	59,264,000	48,957,000	62,450,000	58,483,000	55,735,000	49,291,000	61,427,000	54,278,000	50,130,000	42,773,000	54,554,000	43,487,000	24,714,000	23,565,000	24,784,000	20,148,000	12,716,000	8,398,000	7,575,000	6,831,000	5,278,000	3,238,000	4,406,000
lease liabilities	11,766,000	10,487,000	10,297,000	10,424,000	11,717,000	12,781,000	12,595,000	12,067,000	10,884,000	11,261,000	11,779,000	11,819,000	11,631,000	11,323,000	11,066,000	10,698,000	10,305,000	9,380,000	8,976,000
liabilities for sales of future royalties	63,863,000	57,376,000	49,847,000	48,731,000	46,921,000	42,689,000	29,242,000	29,932,000	23,724,000	3,533,000	875,439,000
other liabilities	2,581,000	3,348,000	4,280,000	4,835,000	15,197,000	14,479,000	12,205,000	10,230,000	10,392,000	9,257,000	4,820,000	4,050,000	3,768,000	3,392,000	1,005,000	471,000											4,759,000	4,702,000	4,836,000	4,944,000	5,119,000	5,228,000	5,414,000	5,589,000	6,393,000	8,845,000	6,073,000	4,480,000	561,000	634,000	684,000	478,000	505,000	533,000	560,000	182,000	200,000
total current liabilities	293,244,000	291,668,000	344,153,000	285,008,000	272,866,000	245,575,000	280,437,000	253,978,000	244,379,000	218,179,000	261,210,000	227,361,000	220,636,000	167,231,000	181,368,000	135,933,000	127,067,000	127,044,000	189,609,000	201,186,000	219,729,000	196,858,000	103,300,000	90,307,000	75,006,000	66,880,000	74,725,000	66,681,000	66,049,000	57,583,000	71,014,000	64,261,000	62,675,000	51,755,000	60,259,000	50,431,000	31,983,000	29,880,000	27,918,000	24,733,000	23,042,000	14,243,000	12,517,000	11,072,000	8,943,000	6,811,000	5,921,000
deferred tax liabilities	30,058,000	30,058,000	30,058,000	30,058,000	30,058,000	30,058,000	30,058,000	31,667,000	31,667,000	31,667,000	31,667,000	33,306,000	33,306,000	33,306,000	33,306,000	33,306,000	33,306,000	33,306,000	33,306,000	33,306,000	33,306,000	33,306,000	33,306,000	31,166,000	31,166,000	31,166,000	31,166,000	31,166,000	31,166,000	31,166,000	31,166,000
total liabilities	1,147,979,000	1,160,681,000	1,241,159,000	1,184,536,000	1,186,019,000	1,166,816,000	1,215,599,000	1,206,426,000	1,182,280,000	1,162,923,000	1,192,950,000	1,149,645,000	642,554,000	587,605,000	599,836,000	551,127,000	540,273,000	543,181,000	605,180,000	602,194,000	618,454,000	623,994,000	481,732,000	152,679,000	139,140,000	121,030,000	110,650,000	102,549,000	102,051,000	93,693,000	107,299,000	69,489,000	68,089,000	57,344,000	66,652,000	59,276,000	38,056,000	34,360,000	28,479,000	25,367,000	23,726,000	14,721,000	13,022,000	11,605,000	9,503,000	6,993,000	9,540,000
noncontrolling interest	7,000,000	7,000,000	7,000,000	7,000,000
stockholders’ equity:
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding in 2025 and in 2024
common stock	96,000	94,000	92,000	92,000	92,000	83,000	82,000				70,000				69,000				67,000				58,000				51,000				44,000				41,000				39,000	39,000	36,000	36,000	32,000	32,000	30,000	30,000
treasury stock	-7,991,000	-7,566,000	-3,593,000	-3,555,000	-3,395,000	-3,332,000	-432,000	-381,000	-381,000	-356,000
deferred compensation obligation	7,991,000	7,566,000	3,593,000	3,555,000	3,395,000	3,332,000	432,000	381,000	381,000	356,000
additional paid-in capital	4,374,333,000	4,252,417,000	4,212,692,000	4,169,298,000	4,123,364,000	3,698,957,000	3,662,346,000	3,298,357,000	3,236,879,000	3,169,371,000	3,140,019,000	3,108,170,000	3,071,000,000	3,028,829,000	2,997,497,000	2,884,695,000	2,850,016,000	2,810,176,000	2,773,195,000	2,260,682,000	2,220,963,000	2,162,667,000	2,086,863,000	2,066,483,000	2,045,685,000	2,013,859,000	1,639,773,000	1,605,412,000	1,559,722,000	1,526,972,000	1,221,762,000	1,123,861,000	1,105,348,000	1,087,028,000	1,003,561,000	915,084,000	837,943,000	827,109,000	816,578,000	806,202,000	509,658,000	501,597,000	324,128,000	321,714,000	259,555,000	258,599,000
accumulated other comprehensive loss	-268,000	-341,000						-2,244,000	-3,098,000	-3,967,000	-6,573,000	-10,222,000	-8,914,000	-6,554,000								-1,545,000	-147,000	-71,000		-148,000	-633,000	-410,000	-654,000	-946,000									-868,000	-39,000	-209,000	-94,000
accumulated deficit	-4,222,875,000	-4,107,924,000	-3,956,844,000	-3,823,459,000	-3,689,943,000	-3,558,345,000	-3,387,661,000	-3,264,471,000	-3,104,822,000	-2,944,994,000	-2,781,022,000	-2,629,189,000	-2,384,083,000	-2,225,921,000	-2,073,601,000	-1,951,143,000	-1,878,145,000	-1,755,717,000	-1,619,576,000	-1,595,565,000	-1,526,720,000	-1,552,035,000	-1,433,010,000	-1,339,205,000	-1,226,211,000	-1,127,039,000	-1,030,283,000	-942,457,000	-855,147,000	-802,419,000	-832,672,000	-750,941,000	-671,714,000	-598,823,000	-530,533,000	-459,246,000	-394,339,000	-337,416,000	-284,659,000	-229,439,000	-190,207,000	-160,420,000	-139,041,000	-122,302,000	-106,454,000
total stockholders’ equity	151,286,000	144,246,000	255,297,000	346,827,000	432,418,000	140,264,000	275,414,000	31,714,000	129,030,000	220,481,000	352,494,000	468,829,000	678,073,000	796,424,000	922,561,000	933,674,000	972,171,000	1,054,582,000	1,154,375,000	666,191,000	695,587,000	609,146,000	653,764,000	727,265,000	819,787,000	886,729,000	608,908,000	662,596,000	703,971,000	723,657,000	383,454,000	365,558,000	429,453,000	488,478,000	473,974,000	455,890,000	443,895,000	489,824,000	531,090,000	576,763,000	319,278,000	341,119,000	184,945,000	199,326,000	153,083,000	165,714,000
total liabilities, noncontrolling interest and stockholders’ equity	1,306,265,000	1,311,927,000	1,503,456,000	1,538,363,000
liabilities and stockholders' equity
commitments and contingencies
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding in 2024 and in 2023
accumulated other comprehensive income			-643,000	896,000	-1,095,000	-431,000	647,000								-1,404,000	54,000	232,000	56,000	689,000	1,013,000	1,284,000				255,000						-5,680,000	-7,404,000	-4,223,000	231,000	905,000	12,000	252,000	92,000					-174,000	-118,000	-48,000	-46,000	11,000
total liabilities and stockholders’ equity					1,618,437,000	1,307,080,000	1,491,013,000	1,238,140,000	1,311,310,000	1,383,404,000	1,545,444,000	1,618,474,000	1,320,627,000	1,384,029,000	1,522,397,000	1,484,801,000	1,512,444,000	1,597,763,000	1,759,555,000	1,268,385,000	1,314,041,000	1,233,140,000	1,135,496,000	879,944,000	958,927,000	1,007,759,000	719,558,000	765,145,000	806,022,000	817,350,000	490,753,000	435,047,000	497,542,000	545,822,000	540,626,000	515,166,000	481,951,000	524,184,000	559,569,000	602,130,000	343,004,000	355,840,000
contract liabilities											1,479,000	2,958,000	4,437,000	5,867,000	7,609,000		3,912,000	19,221,000	59,219,000	102,898,000
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding in 2023 and in 2022
prepaid expenses and other current assets								46,029,000	51,377,000	67,375,000	68,926,000	70,980,000	77,461,000	63,020,000	71,745,000	69,193,000	63,933,000	68,034,000	57,630,000	64,264,000	58,196,000	64,788,000	51,397,000	49,169,000	46,612,000	44,995,000	42,858,000	49,671,000	36,844,000	33,953,000	28,700,000	19,376,000	19,685,000	19,224,000	20,136,000	18,944,000	17,799,000	17,088,000	13,060,000	12,324,000	9,430,000	6,877,000	5,929,000	5,547,000	4,945,000	4,239,000	1,848,000
equity investments								4,039,000	5,458,000	5,197,000	5,531,000	13,786,000	15,412,000	25,596,000	34,925,000	86,215,000	103,710,000	134,756,000	155,375,000
right-of-use assets								26,427,000	19,222,000	22,949,000	25,961,000	28,751,000	31,245,000	32,699,000	34,936,000	36,696,000	38,619,000	38,511,000	40,524,000	37,597,000	37,067,000	35,827,000		31,711,000	33,356,000	23,024,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of september 30, 2023 and december 31, 2022
common stock — 250,000,000 shares authorized; 72,174,307 and 70,197,297 shares issued and outstanding as of september 30, 2023 and december 31, 2022, respectively								72,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of june 30, 2023 and december 31, 2022
common stock — 250,000,000 shares authorized; 71,465,424 and 70,197,297 shares issued and outstanding as of june 30, 2023 and december 31, 2022, respectively									71,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of march 31, 2023 and december 31, 2022
common stock — 250,000,000 shares authorized; 70,660,249 and 70,197,297 shares issued and outstanding as of march 31, 2023 and december 31, 2022, respectively										71,000
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding as of december 31, 2022 and december 31, 2021
liabilities and stockholders’ equity
liabilities related to the sale of future royalties												862,063,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of september 30, 2022 and december 31, 2021
common stock — 250,000,000 shares authorized; 70,079,777 and 69,344,998 shares issued and outstanding as of september 30, 2022 and december 31, 2021, respectively												70,000
liability related to the sale of future royalties													358,942,000	355,633,000	351,786,000	348,073,000	344,039,000	340,211,000	335,665,000	331,034,000	325,783,000	320,836,000	315,369,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of june 30, 2022 and december 31, 2021
common stock — 250,000,000 shares authorized; 70,010,398 and 69,344,998 shares issued and outstanding as of june 30, 2022 and december 31, 2021, respectively													70,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of march 31, 2022 and december 31, 2021
common stock — 250,000,000 shares authorized; 69,796,940 and 69,344,998 shares issued and outstanding as of march 31, 2022 and december 31, 2021, respectively														70,000
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding as of december 31, 2021 and december 31, 2020
preferred stock — 25,000,000 shares authorized; nil outstanding as of september 30, 2021 and december 31, 2020
common stock — 250,000,000 shares authorized; 67,961,963 and 66,818,520 shares issued and outstanding as of september 30, 2021 and december 31, 2020, respectively																68,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of june 30, 2021 and december 31, 2020
common stock — 250,000,000 shares authorized; 67,764,950 and 66,818,520 shares issued and outstanding as of june 30, 2021 and december 31, 2020, respectively																	68,000
property and equipment																		87,570,000		48,773,000	48,339,000	47,596,000	44,348,000	31,877,000	25,317,000	21,696,000	20,046,000	19,828,000	20,858,000	20,830,000	21,837,000	16,030,000	16,405,000	16,517,000	17,055,000	18,226,000	17,054,000	13,418,000	7,373,000	6,285,000	4,772,000	3,514,000	3,033,000	2,621,000	2,497,000	1,777,000	1,325,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of march 31, 2021 and december 31, 2020
common stock — 250,000,000 shares authorized; 67,439,477 and 66,818,520 shares issued and outstanding as of march 31, 2021 and december 31, 2020, respectively																		67,000
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding as of december 31, 2020 and 2019
short-term investments																				568,034,000	477,777,000	365,088,000	321,646,000	404,481,000	486,949,000	445,604,000	346,274,000	420,142,000	436,278,000	314,616,000	134,005,000	310,659,000	308,897,000	265,689,000	219,028,000	254,150,000	336,734,000	341,092,000	343,428,000	281,697,000	273,678,000	164,526,000	163,163,000	147,807,000	135,819,000	109,950,000	45,950,000
investments in equity securities																				129,320,000
long-term investments																					4,068,000	41,711,000	5,174,000							29,907,000	9,975,000	24,964,000	57,802,000	80,862,000	117,963,000	76,211,000	50,021,000	75,932,000	99,259,000	133,492,000
short-term lease liabilities																				7,785,000	7,258,000	7,487,000	7,235,000	7,290,000	6,999,000	5,259,000
long-term lease liabilities																				36,668,000	36,308,000	34,958,000	29,757,000	31,206,000	32,968,000	22,984,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of september 30, 2020 and december 31, 2019
common stock — 250,000,000 shares authorized; 60,815,690 and 57,838,220 shares issued and outstanding as of september 30, 2020 and december 31, 2019, respectively																				61,000
receivable related to daiichi sankyo license agreements																					8,473,000
investment in arcturus equity securities																					140,220,000	35,420,000	27,752,000	26,333,000	24,167,000
short-term contract liability																					131,570,000	107,247,000
long-term contract liability																					3,328,000	38,036,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of june 30, 2020 and december 31, 2019
common stock — 250,000,000 shares authorized; 60,413,756 and 57,838,220 shares issued and outstanding as of june 30, 2020 and december 31, 2019, respectively																					60,000
receivable related to daiichi sankyo license agreement																						125,550,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of march 31, 2020 and december 31, 2019
common stock — 250,000,000 shares authorized; 59,488,873 and 57,838,220 shares issued and outstanding as of march 31, 2020 and december 31, 2019, respectively																						59,000
right-of-use lease assets																							30,328,000
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding as of december 31, 2019 and 2018
preferred stock — 25,000,000 shares authorized; nil outstanding as of september 30, 2019 and december 31, 2018
common stock — 250,000,000 shares authorized; 57,749,890 and 50,860,588 shares issued and outstanding as of september 30, 2019 and december 31, 2018, respectively																								58,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of june 30, 2019 and december 31, 2018
common stock — 250,000,000 shares authorized; 57,665,375 and 50,860,588 shares issued and outstanding as of june 30, 2019 and december 31, 2018, respectively																									58,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of march 31, 2019 and
december 31, 2018
common stock — 250,000,000 shares authorized; 57,303,888 and 50,860,588 shares issued
and outstanding as of march 31, 2019 and december 31, 2018, respectively																										57,000
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding as of december 31, 2018 and 2017
preferred stock — 25,000,000 shares authorized; nil outstanding as of september 30, 2018 and
december 31, 2017
common stock — 250,000,000 shares authorized; 50,533,070 and 44,167,071 shares issued
and outstanding as of september 30, 2018 and december 31, 2017, respectively																												51,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of june 30, 2018 and
common stock — 250,000,000 shares authorized; 50,116,056 and 44,167,071 shares issued
and outstanding as of june 30, 2018 and december 31, 2017, respectively																													50,000
restricted cash																														542,000	461,000	461,000	461,000	271,000	1,411,000	1,411,000	1,482,000	1,291,000	150,000	912,000	1,071,000	1,071,000	744,000	744,000	744,000	744,000	451,000
deferred rent—current portion																														723,000	701,000	695,000	669,000	637,000	341,000	328,000	315,000	303,000	192,000	163,000	155,000	90,000	85,000	80,000	75,000	78,000	78,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of march 31, 2018 and
common stock — 250,000,000 shares authorized; 49,665,203 and 44,167,071 shares issued
and outstanding as of march 31, 2018 and december 31, 2017, respectively																														50,000
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding as of december 31, 2017 and 2016
preferred stock — 25,000,000 shares authorized; nil outstanding as of september 30, 2017 and
december 31, 2016
common stock — 250,000,000 shares authorized; 42,488,312 and 41,240,230 shares issued
and outstanding as of september 30, 2017 and december 31, 2016, respectively																																42,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of june 30, 2017 and
common stock — 250,000,000 shares authorized; 42,428,124 and 41,240,230 shares issued
and outstanding as of june 30, 2017 and december 31, 2016, respectively																																	42,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of march 31, 2017 and
common stock — 250,000,000 shares authorized; 42,273,429 and 41,240,230 shares issued
and outstanding as of march 31, 2017 and december 31, 2016, respectively																																		42,000
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding as of december 31, 2016 and 2015
preferred stock — 25,000,000 shares authorized; nil outstanding as of september 30, 2016 and
december 31, 2015
common stock — 250,000,000 shares authorized; 40,052,032 and 38,882,394 shares issued
and outstanding as of september 30, 2016 and december 31, 2015, respectively																																				40,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of june 30, 2016 and december 31, 2015
common stock — 250,000,000 shares authorized; 39,046,247 and 38,882,394 shares issued and outstanding as of june 30, 2016 and december 31, 2015, respectively																																					39,000
preferred stock — 25,000,000 shares authorized; nil outstanding as of march 31, 2016 and december 31, 2015
common stock — 250,000,000 shares authorized; 38,992,346 and 38,882,394 shares issued and outstanding as of march 31, 2016 and december 31, 2015, respectively																																						39,000
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding as of december 31, 2015 and 2014
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding as of september 30, 2015 and december 31, 2014
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding as of june 30, 2015 and december 31, 2014
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding as of march 31, 2015 and december 31, 2014
liabilities, convertible preferred stock and stockholders’ equity
convertible preferred stock warrant liability																																															3,419,000
series a redeemable convertible preferred stock, par value of 0.001 per share — nil and 35,377,556 shares authorized as of december 31, 2014 and 2013; nil and 34,349,894 shares issued and outstanding as of december 31, 2014 and 2013
series b convertible preferred stock, par value of 0.001 per share—nil and 27,081,680 shares authorized, issued and outstanding as of december 31, 2014 and 2013
stockholders’ equity
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding as of december 31, 2014 and 2013
total liabilities, convertible preferred stock and stockholders’ equity																																											197,967,000	210,931,000	162,586,000	172,707,000
series a redeemable convertible preferred stock, par value of 0.001 per share—nil and 35,377,556 shares authorized; nil and 34,349,894 shares issued and outstanding as of september 30, 2014 and december 31, 2013
series b convertible preferred stock, par value of 0.001 per share—nil and 27,081,680 shares authorized, issued and outstanding as of september 30, 2014 and december 31, 2013
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding as of september 30, 2014 and december 31, 2013
series a redeemable convertible preferred stock, par value of 0.001 per share—nil and 35,377,566 shares authorized; nil and 34,349,894 shares issued and outstanding as of june 30, 2014 and december 31, 2013
series b convertible preferred stock, par value of 0.001 per share—nil and 27,081,680 shares authorized, issued and outstanding as of june 30, 2014 and december 31, 2013
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding as of june 30, 2014 and december 31, 2013
series a redeemable convertible preferred stock, par value of 0.001 per share—nil and 35,377,566 shares authorized; nil and 34,349,894 shares issued and outstanding as of march 31, 2014 and december 31, 2013
series b convertible preferred stock, par value of 0.001 per share—nil and 27,081,680 shares authorized, issued and outstanding as of march 31, 2014 and december 31, 2013
preferred stock, par value of 0.001 per share—25,000,000 shares authorized; nil outstanding as of march 31, 2014 and december 31, 2013
deficit accumulated during the development stage																																														-92,869,000	-74,836,000
liabilities, convertible preferred stock and stockholders’ deficit
series a redeemable convertible preferred stock, par value of 0.001 per share—35,377,556
shares authorized as of december 31, 2012 and 2013; 34,349,894 shares issued and outstanding as of december 31, 2012 and 2013; redemption value of 138,155 as of december 31, 2013																																															51,001,000
series b convertible preferred stock, par value of 0.001 per share—27,081,680 shares
authorized, issued and outstanding as of december 31, 2012 and 2013; aggregate liquidation preference of 76,739 as of december 31, 2013																																															73,929,000
stockholders’ deficit:
and 3,766,289 shares issued and outstanding as of december 31, 2012 and 2013																																															4,000
total stockholders’ deficit																																															-74,821,000
total liabilities, convertible preferred stock and stockholders’ deficit																																															59,649,000
operating expenses:
research and development																																															12,641,000
general and administrative																																															3,344,000
total operating expenses																																															15,985,000
income from operations																																															-15,985,000
other income, net:
interest income																																															1,000
interest expense
other income																																															-350,000
total other income																																															-349,000
net income																																															-16,334,000
net income attributable to common stockholders																																															-19,561,000
net income per share
diluted																																															-14,200
shares used in computing net income per share attributable to common stockholders, basic and diluted																																															1,377,207,000

We provide you with 20 years of balance sheets for Ultragenyx Pharmaceutical stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ultragenyx Pharmaceutical. Explore the full financial landscape of Ultragenyx Pharmaceutical stock with our expertly curated balance sheets.

The information provided in this report about Ultragenyx Pharmaceutical stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.